Cancer drug maker BiPar sells to Sanofi-aventis for $500M » VentureBeat
VENTUREBEAT.COM - BiPar Sciences, maker of tumor-targeting cancer treatments, will be acquired by public global pharmaceutical company Sanofi-aventis. The two companies have signed a binding agreement that could deliver more than $500 million to BiPar, divided into varying milestone payments.Based in Brisbane, Calif., BiPar creates therapies, primarily for breast and ovarian cancer patients, that use inhibitors to...
First tweeted by RSS_VentureBeat.
From the Front Page
Socialsafe.net
- Comments
- Tweets (4)
Tweets
Sorry there have been no tweets in the last 7 days.
